Analyst Price Targets — ALMS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 10, 2026 8:05 pm | Christopher Raymond | Raymond James | $46.00 | $28.10 | StreetInsider | Raymond James Starts Alumis Inc (ALMS) at Strong Buy |
| January 21, 2026 9:36 am | — | Chardan Capital | $37.00 | $26.06 | TheFly | Alumis initiated with a Buy at Chardan |
| January 21, 2026 8:52 am | Janani Sundararajan | Loop Capital Markets | $37.00 | $26.06 | StreetInsider | Chardan Capital Markets Starts Alumis Inc (ALMS) at Buy |
| January 9, 2026 11:11 am | — | H.C. Wainwright | $40.00 | $18.18 | TheFly | Alumis price target raised to $40 from $20 at H.C. Wainwright |
| January 7, 2026 11:43 am | — | Morgan Stanley | $33.00 | $16.23 | TheFly | Alumis price target raised to $33 from $22 at Morgan Stanley |
| January 7, 2026 11:36 am | Yatin Suneja | Guggenheim | $32.00 | $16.23 | TheFly | Alumis price target raised to $32 from $18 at Guggenheim |
| January 6, 2026 8:49 pm | Jeff Jones | Oppenheimer | $50.00 | $16.23 | TheFly | Alumis price target raised to $50 from $25 at Oppenheimer |
| January 6, 2026 8:47 pm | — | Leerink Partners | $32.00 | $16.23 | TheFly | Alumis price target raised to $32 from $20 at Leerink |
| January 6, 2026 3:41 pm | Derek Archila | Wells Fargo | $39.00 | $16.97 | TheFly | Alumis price target raised to $39 from $17 at Wells Fargo |
| December 18, 2025 2:54 pm | Mitchell Kapoor | H.C. Wainwright | $20.00 | $11.00 | TheFly | Alumis price target raised to $20 from $14 at H.C. Wainwright |
Latest News for ALMS
Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials
Alumis Inc. is upgraded to Buy, reversing a prior Sell, based on strong Phase 3 envudeucitinib psoriasis data and pipeline potential. Envudeucitinib demonstrated efficacy comparable to JNJ's newly approved Icotyde, with 74% PASI 75 and 59% sPGA 0/1 at week 16. ALMS targets NDA submission for envudeucitinib in 2H 2026, with additional data in psoriatic arthritis and SLE expected in 2026.
– Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) –
– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib – – Alumis to host investor webcast on Sunday, March 29, 2026, at 5:00 pm MDT / 7:00 pm EDT – SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage…
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 9, 2026, at…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ALMS.
U.S. House Trading
No House trades found for ALMS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.